Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Risk-reducing surgery and surgical menopause
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Acute postoperative complications need urgent assessment
After hysterectomy or bilateral salpingo-oophorectomy, collapse, heavy bleeding, escalating abdominal pain, fever, breathlessness, chest pain, unilateral leg swelling, vomiting or failure to pass urine can indicate haemorrhage, sepsis, venous thromboembolism, urinary injury or bowel complication.
Action: Assess observations and resuscitation needs immediately, examine the abdomen and wounds, obtain urgent senior surgical review, and use emergency imaging, antimicrobial, thromboembolic or return-to-theatre pathways according to the suspected complication.
Purpose and principles
Plan gene- and age-specific gynaecological risk-reducing surgery through shared decision making, then prevent and manage the immediate reproductive, menopausal, bone, cardiovascular and psychosexual consequences.
Risk-reducing surgery is an elective prevention decision, not an automatic response to a genetic result. Confirm the pathogenic variant in an accredited pathway, construct the three-generation history, estimate lifetime and near-term ovarian risk, and establish whether the person has ovaries, tubes and a uterus. Explore fertility plans, previous cancer, breast-risk management, menopause expectations, sexual wellbeing, disability, gender identity, caring duties and the practical effect of recovery. A variant of uncertain significance should not be treated as a pathogenic variant or used alone to justify irreversible surgery.
NICE recommends discussing risk-reducing surgery when total lifetime ovarian-cancer risk is at least 5%, whether that risk comes from a pathogenic variant or a strong verified family history. Timing is deliberately gene specific. The NG241 table lists bilateral salpingo-oophorectomy no earlier than age 35 for BRCA1 and 40 for BRCA2. For RAD51C, RAD51D, BRIP1 or PALB2, bilateral salpingo-oophorectomy is listed no earlier than 45 when calculated lifetime ovarian risk reaches 5%. Family age at diagnosis and an individual's health can move the final decision within a specialist familial ovarian cancer MDT discussion.
Indications, selection and cautions
Eligible prevention discussion
A confirmed pathogenic variant or verified family history producing at least 5% lifetime ovarian-cancer risk triggers specialist discussion, not immediate booking for an operation.
Gene-specific operation
BRCA-related ovarian prevention generally uses bilateral salpingo-oophorectomy, whereas MLH1, MSH2 and MSH6 Lynch risk usually makes hysterectomy relevant as well.
Abrupt ovarian failure
Hot flushes, insomnia, mood change, vaginal dryness, dyspareunia and reduced libido soon after bilateral oophorectomy suggest surgical menopause rather than a gradual perimenopause.
Occult pathological disease
Serous tubal intraepithelial carcinoma, atypical endometrial pathology or invasive cancer in a risk-reducing specimen converts prevention follow-up into specialist oncological assessment.
Residual peritoneal risk
New ascites, persistent abdominal distension, early satiety or pelvic pain still needs diagnostic assessment after salpingo-oophorectomy because risk is reduced, not abolished.
Red flags requiring action
Haemodynamic disturbance, abdominal distension, increasing pain or unexpected vaginal or wound bleeding after surgery requires same-day surgical assessment.
Fever, rigors, offensive discharge, wound erythema or confusion may represent pelvic, urinary or wound sepsis and should not be attributed to normal recovery.
Assessment before treatment
01Verified germline report and pedigreeFirst step
Why
Confirm the familial cancer syndrome and place the variant alongside cancer diagnoses and ages in relatives.
Interpretation and limitations
A pathogenic or likely pathogenic result informs risk management; a variant of uncertain significance does not justify irreversible surgery without other validated risk evidence.
02Personalised ovarian-risk calculation
Why
Estimate lifetime and near-term risk before discussing the operation and timing.
Interpretation and limitations
A total lifetime risk of at least 5% supports a surgery discussion, while gene, current age, family history and competing morbidity determine when benefit outweighs premature-menopause harm.
03Preoperative pelvic assessment
Why
Identify symptoms, examination findings or imaging abnormalities that could represent existing cancer before preventive surgery.
Interpretation and limitations
A suspicious mass, ascites, abnormal bleeding or concerning scan requires tumour-site assessment and oncology MDT planning rather than a routine prophylactic operation.
04Specialist histopathology
Why
Examine tubes, ovaries and any uterus through the risk-reducing specimen protocol for occult precursor or invasive disease.
Interpretation and limitations
A benign report closes the operative episode but not residual peritoneal awareness; precursor or cancer findings require staging review and a new follow-up plan.
Treatment approach
01DecisionMatch irreversible surgery to verified riskFirst stepA pathogenic variant or strong family history raises concern about ovarian or endometrial cancer.+
1Confirm the laboratory result, relevant organs, personal cancer history, pedigree and calculated ovarian risk through genetics and the familial ovarian cancer MDT.
2Explain gene-specific timing, the operation proposed, residual cancer risk, possible occult findings, fertility loss, recovery and alternatives including the limitations of surveillance.
3Record informed preference after reproductive, menopause and psychological support, and revisit the decision when someone chooses to defer without treating delay as loss of care.
02OperationUse a preventive oncology protocolThe person elects risk-reducing surgery after completing shared decision making.+
1Check pregnancy, comorbidity, thrombosis prevention, imaging or symptom findings and the agreed plan for hysterectomy, salpingo-oophorectomy and postoperative hormones.
Regimens, contraindications and interactions
Replaces ovarian oestrogen after premenopausal bilateral salpingo-oophorectomy, treating vasomotor and genitourinary symptoms and reducing consequences of early hormone deprivation until the natural menopause age review.
Transdermal estradiol with uterine protection when required
One licensed example starts estradiol 50 micrograms per 24 hours by transdermal patch, replaced twice weekly continuously; titrate to response and add a licensed progestogen for at least 12 to 14 days of each 28-day cycle whenever the uterus remains.
Confirm breast-cancer history, unexplained bleeding, thromboembolic and hepatic risk, migraine and medicine interactions; follow the chosen product's SmPC, investigate unscheduled bleeding and never omit endometrial protection with systemic oestrogen when a uterus is present.
Complications, monitoring and follow-up
Review operative histology and make sure any tubal precursor, atypia or cancer reaches the relevant oncology MDT rather than remaining in a routine postoperative letter.
Assess wounds, pain, bowel and urinary function, thrombosis symptoms, infection and recovery of mobility at the early postoperative review.
After starting HRT, review symptom control, bleeding, blood pressure, adverse effects, adherence and formulation suitability, adjusting rather than abandoning treatment after one poorly tolerated product.
Track bone and cardiometabolic risk through smoking, activity, weight, blood pressure, lipids, diabetes and fracture assessment, using DXA when the overall risk profile indicates it.
Retain rapid access for persistent abdominal symptoms despite risk-reducing surgery and review the HRT plan around age 51 with the person's current risks and preferences.
Special situations
Threshold starts a conversation
A lifetime ovarian risk of 5% supports discussing surgery; it does not erase gene-specific age, fertility, menopause harm or patient preference.
PMS2 is different
PMS2 predominantly raises endometrial risk, so hysterectomy and ovary removal are separated according to ovarian family history, age and menopausal status.
Salpingectomy alone remains experimental
Removing tubes while delaying ovarian removal may postpone menopause, but prevention equivalence is unproven and NICE limits this strategy to trials.
Pathology is part of prevention
A meticulous tubal and ovarian protocol can discover occult precursor or invasive disease that a routine benign specimen process might miss.
HRT replaces missing physiology
Before the average menopause age, the decision addresses abrupt hormone deprivation and long-term health as well as relief of hot flushes.
Common pitfalls
01
Treating a variant of uncertain significance as a confirmed pathogenic variant and recommending irreversible surgery from that result alone.
02
Quoting one universal operation or age without distinguishing BRCA, moderate-penetrance ovarian genes, Lynch variants and the verified family history.
03
Describing bilateral salpingo-oophorectomy as eliminating all future pelvic serous cancer risk rather than acknowledging residual primary peritoneal cancer.
04
Failing to discuss fertility preservation and the permanent loss of natural conception before removing both ovaries or the uterus.
05
Withholding HRT automatically after premenopausal surgery despite no breast-cancer history, or prescribing oestrogen alone while a uterus remains.
06
Offering interval salpingectomy with delayed oophorectomy as established equivalent prevention outside a clinical trial.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Selecting Lynch risk-reducing surgery
A 38-year-old with a confirmed pathogenic MSH2 variant has completed their family and asks which gynaecological risk-reducing operation NICE lists for this syndrome. Which answer is most accurate?
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Lynch syndrome changes the organs at risk. For MLH1, MSH2 or MSH6, NICE lists total hysterectomy with bilateral salpingo-oophorectomy no earlier than 35 to reduce both endometrial and ovarian cancer. A heterozygous PMS2 variant predominantly raises endometrial risk: NICE advises considering total hysterectomy alone no earlier than 45 when there is no ovarian-cancer family history, with oophorectomy added only after considering verified family history, age and menopausal status. Do not add hysterectomy routinely for an ovarian-risk gene without a separate endometrial or gynaecological indication.
Before surgery, explain precisely what will be removed and what risk remains. Bilateral salpingo-oophorectomy removes both tubes and ovaries and substantially reduces tubo-ovarian cancer risk, but it cannot eliminate primary peritoneal cancer. Hysterectomy removes the uterus and ends the possibility of carrying a pregnancy; removal of both ovaries also removes the possibility of using the person's own future oocytes. Offer timely reproductive-medicine referral for embryo or oocyte cryopreservation where appropriate, while avoiding promises about success or delay that have not been agreed with the specialist teams.
Use minimally invasive surgery unless laparotomy is clinically more appropriate. The operation needs a preventive oncology protocol rather than the handling of routine benign specimens: inspect peritoneal surfaces, obtain peritoneal washings, biopsy any suspicious lesion when safe and submit the tubes and ovaries for the detailed pathology process. An occult tubal precursor or invasive malignancy changes staging and management. An unexpected result should be communicated through the gynaecological oncology MDT, and the patient should not be falsely reassured by the original preventive intent.
Removing functioning ovaries produces abrupt surgical menopause. Hot flushes, night sweats, sleep disturbance, mood change, vaginal dryness, urinary symptoms, reduced arousal, dyspareunia and loss of libido can appear quickly. Longer hormone deprivation affects bone density and may worsen cardiovascular risk. The experience can intersect with grief about fertility, cancer anxiety, body image, relationships and gender dysphoria. Counselling before the operation allows an HRT or alternative plan, baseline risk review and realistic preparation rather than leaving treatment until severe symptoms develop.
NICE advises HRT until the average natural menopause age, usually about 51, after premenopausal risk-reducing bilateral salpingo-oophorectomy in someone without breast cancer. When the uterus remains, endometrial protection requires a progestogen with systemic oestrogen; after hysterectomy, oestrogen-only therapy is normally used. Begin as soon as clinically appropriate after surgery and individualise route, dose and formulation. Transdermal oestrogen may be useful when venous-thromboembolism or metabolic considerations favour avoiding oral exposure, but contraindications, migraine, bleeding and treatment interactions still need review.
A history of breast cancer requires liaison with the breast oncology team rather than unilateral initiation or permanent refusal of HRT. Consider receptor status, recurrence risk, endocrine therapy and symptom severity. Vaginal symptoms may respond to lubricants, moisturisers, pelvic-health care and, in eligible people without breast cancer, vaginal oestrogen. Vasomotor symptoms can be managed with appropriate non-hormonal medicines when systemic HRT is unsuitable, but interactions matter; for example, some antidepressants interfere with tamoxifen metabolism.
Recovery and long-term care need named ownership. Review histology, wounds, bowel and bladder function, venous-thromboembolism prevention, menopausal symptoms and HRT tolerance. Encourage graded activity, smoking cessation, adequate dietary calcium, vitamin D sufficiency and weight-bearing exercise. Assess bone-fracture risk and arrange DXA when age, early menopause or other risk factors justify it. Revisit HRT near age 51 as an individual benefit-risk decision rather than stopping abruptly or continuing indefinitely by default.
Key points
Risk-reducing surgery is considered only after validated genetic or familial risk assessment, completed reproductive plans and multidisciplinary discussion of the person's age, variant, family history and competing health priorities.
NICE uses a total lifetime ovarian-cancer risk of at least 5% as the threshold for discussing surgery, but the appropriate operation and timing still depend on the pathogenic variant and individual risk trajectory.
NICE lists bilateral salpingo-oophorectomy no earlier than 35 for BRCA1, 40 for BRCA2 and 45 for RAD51C, RAD51D, BRIP1 or PALB2 when lifetime ovarian risk is at least 5%; earlier surgery needs individualised assessment.
For MLH1, MSH2 or MSH6 Lynch syndrome, hysterectomy with bilateral salpingo-oophorectomy is listed no earlier than 35 because both endometrial and ovarian risk are relevant; PMS2 requires a different, personalised discussion.
Bilateral salpingo-oophorectomy before natural menopause causes immediate irreversible ovarian failure, infertility and loss of endogenous ovarian hormones; consent must cover vasomotor, sexual, bone, cardiovascular and psychological effects.
Offer HRT until about age 51 after premenopausal risk-reducing bilateral salpingo-oophorectomy when there is no previous breast cancer; use combined HRT when the uterus remains and oestrogen alone after hysterectomy.
Sudden dyspnoea, pleuritic chest pain, haemoptysis, hypoxia or unilateral leg swelling requires emergency assessment for venous thromboembolism.
New calf swelling, persistent vomiting, inability to pass urine, faeculent vaginal discharge or peritonism raises concern for thrombotic, urinary or bowel injury.
Unexpected invasive or premalignant disease in the prophylactic specimen requires prompt gynaecological oncology review before assuming surgery completed risk management.
05Bone and cardiometabolic assessment
Why
Establish modifiable health risks after early loss of ovarian hormones and guide monitoring.
Interpretation and limitations
Blood pressure, smoking, lipids, diabetes risk, fracture history and selective DXA identify interventions; DXA is not required solely to prove that surgical menopause occurred.
2Use minimally invasive surgery when appropriate, take peritoneal washings, inspect all surfaces, biopsy suspicious lesions safely and avoid incomplete removal of fimbrial tissue.
3Ensure specialist pathology processing, communicate the result directly and refer unexpected precursor or malignant disease to the gynaecological oncology MDT.
03Menopause carePrevent avoidable long-term harmBoth functioning ovaries are removed before the average natural menopause age.+
1Start an individualised HRT plan as soon as clinically appropriate when there is no breast-cancer contraindication, adding endometrial protection whenever the uterus remains.
2Review vasomotor, sleep, mood, sexual, urinary and bleeding symptoms alongside blood pressure, thrombotic factors, adherence and product-specific cautions.
3Promote bone and cardiovascular health, coordinate breast-oncology advice when relevant and reassess the benefit-risk plan near age 51 rather than applying an automatic stop rule.
A previous breast cancer does not create a generic prescribing rule: liaise with the breast cancer team before HRT, considering tumour biology, current endocrine treatment, symptom burden and non-hormonal options.
Salpingectomy with delayed oophorectomy does not yet have equivalent cancer-prevention evidence and NICE restricts this risk-reducing strategy to a clinical trial.